Home News

First nine months 2020 results presentation

Operating income, growth figures, profitability and how our products have behaved.

Thu, 05/11/2020 - 00:00 0 min
Download related document
No votes yet
 
Related
ROVI acquires Falithrom® for the German market
Laboratorios Farmacéuticos Rovi, S.A. (“ROVI”) has announced the purchase of Falithrom®, which was owned by Hexal AG (“Hexal”), a company...
1 min
09/01/2019
9M 2018 Results presentation
0 min
06/11/2018
9M 2018 Results Press Release
0 min
06/11/2018